Trial Profile
A Phase I Open Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Recombinant Mycobacterium Tuberculosis Vaccine, Mtb72F With AS02A Adjuvant, When Administered Intramuscularly to Healthy PPD-Negative Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 24 Dec 2014 New trial record